About Evotec SE ABOUT EVOTEC WORLDWIDE HISTORY MANAGEMENT SUPERVISORY BOARD FAQS Evotec’s mission is to discover and develop highly effective therapeutics and make them globally available to the patients who need them. To this end, Evotec has established itself as a global platform company, leveraging its data-driven multimodality platform for both proprietary as well as partnered research, and applying a unique combination of innovative technologies for the discovery and development of first-in-class and best-in-class pharmaceutical products. Its network of partners includes all Top 20 Pharma and hundreds of biotechnology companies, academic institutions, and other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and make them accessible to patients worldwide. To-date, the Company has established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 4,000 highly qualified people at 14 sites in six countries across Europe and the USA. The Company’s sites in Hamburg (HQ), Cologne, Goettingen, and Munich (Germany), Lyon and Toulouse (France), Abingdon and Alderley Park (UK), Verona (Italy), Orth (Austria), as well as in Branford, Princeton, Seattle and Watertown (USA) offer highly synergistic technologies and services and operate as complementary clusters of excellence. “Our data-driven R&D Autobahn to Cures will deliver speed and innovation efficiency for accessible medicines of the future.” Dr Werner Lanthaler, CEO of Evotec Action Plan 2025: “The data-driven R&D Autobahn to Cures” Evotec’s strategy is clearly focused on highest quality science, superior platforms, and highly efficient processes that lead to significant, long-term productivity improvements in the industry. In essence, it aims to assess disease relevance at the molecular and therefore the patient-specific level as early as possible. This approach is expected to yield new insights into the efficacy and safety of a drug candidate early on rather than during advanced clinical trials, which is the current standard. The objective of this method is much broader and faster access to more effective, targeted therapies for more patients. The eight cornerstones of the Action Plan 2025 are: EVOiR&D – integrated data-driven research & development EVOpanOmics – industrialised high-throughput multi-omics platform EVOpanHunter – advanced data analysis and prediction platform EVOcells – from cells to therapies EVOgenes – from genes to therapies EVOaccess – Just – Evotec Biologics & J.POD® – Biologics for all EVOequity – BRIDGEs & Operational Venturing EVOroyalty – co-own & share products All eight elements are accelerated by the best possible human databases and state-of-the-art artificial intelligence tools for research and development projects. EVT EXECUTE & EVT INNOVATE Evotec’s “data-driven R&D Autobahn to Cures” addresses the industry’s need to discover and develop multiple classes of innovative active substances, including small molecules, biologics as well as cell, gene, and RNA-targeted therapies. Both of Evotec’s segments, EVT Execute and EVT Innovate, operate from a common scientific platform. Through EVT Execute, Evotec provides stand-alone or fully integrated drug discovery and development solutions spanning the entire value chain from early drug discovery to clinical development and beyond. Within EVT Innovate, Evotec leverages its proprietary technology platforms to develop new drug discovery projects, assets and platforms, both internally and through collaborations. This creates starting points for strategic partnerships with pharmaceutical and leading biotech companies. Within EVT Innovate, Evotec also focuses on accelerating innovations through various collaborative models, partnering with academic institutions, other biotech companies, pharmaceutical companies or even a combination of these within its academic BRIDGE partnerships. Evotec worldwide History Management Supervisory Board Thursday, November 25th 2021 Previous Next -2 °C Munich Imprint Privacy Policy Legal notice T&Cs RSS RSS Twitter LinkedIn EVOTEC @Evotec Our presentation at #EBF2021 is today at 17:00 CET | Quantification of two mAbs using both ELISA and LC-MS/MS gener… https://t.co/M5X67v2V5J 11:10 AM - 25 NOVEMBER 2021